Assessment of prostate cancer morbidity in the Samarsky Region, 1989-1998
Gubanov, E.S.; Prianichnikova, M.B.
Voprosy Onkologii 50(1): 38-40
2004
ISSN/ISBN: 0507-3758 PMID: 15088518 Document Number: 582907
Document emailed within 1 workday
Related Documents
Ous, S.; Fryjordet, A.; Waaler, G. 1974: Cancer of the prostate. Morbidity and mortality with estrogen therapy Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 94(12): 748-751Akimoto, T.; Niibe, H. 2000: Recto-vesical morbidity in radiation therapy for prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 284-287
Leewansangtong, S.; Soontrapa, S.; Nualyong, C.; Srinualnad, S.; Taweemonkongsap, T.; Amornvesukit, T. 2005: Is radical prostatectomy in thai men a high morbidity surgery for localized or locally advanced prostate cancer? Journal of the Medical Association of Thailand 88(12): 1833-1837
Kakuda, J.T.; Stuntz, M.; Trivedi, V.; Klein, S.R.; Vargas, H.I. 1999: Objective assessment of axillary morbidity in breast cancer treatment American Surgeon 65(10): 995-998
Perez, C.A.; Michalski, J.; Mansur, D. 2005: Clinical assessment of outcome of prostate cancer (TCP, NTCP) Rays 30(2): 109-120
Fosså, S.D.; Aass, N.; Opjordsmoen, S. 1994: Assessment of quality of life in patients with prostate cancer Seminars in Oncology 21(5): 657-661
Greco, C.; Castiglioni, S.; Fodor, A.; Mazzetta, C.; De Cobelli, O.; Orecchia, R. 2004: Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology Tumori 90(6): 567-572
Reznikov, A.G.; Salivonyk, O.A.; Sotkis, A.G.; Shuba, Y.M. 2015: Assessment of gold nanoparticle effect on prostate cancer LNCaP cells Experimental Oncology 37(2): 100-104
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romas, N.A.; Veenema, R.J.; Hsu, K.C.; Tomashefsky, P.; Lattimer, J.K.; Tannenbaum, M. 1979: Bone marrow acid phosphatase in prostate cancer: an assessment by immunoassay and biochemical methods Transactions of the American Association of Genito-Urinary Surgeons 71: 26-30
Kharchenko, V.P.; Kaprin, A.D.; Adzhamatov, S.R. 2004: A densitometric assessment of skeletal mineral levels in prostate cancer patients treated with hormones Voprosy Onkologii 50(5): 595-598
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Peszyński, J.; Klonowski, S.; Zurawska-Poleszak, S.; Abramowicz, E. 1976: Epidemiological and clinical assessment of laryngeal cancer in the Lublin region in 1974 Polski Tygodnik Lekarski 31(34): 1477-1479
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910